dipyridamole has been researched along with Apolipoprotein B-100, Familial Defective in 6 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to examine the relationship between plasma asymmetric dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects with borderline hypertension (BHT) and familial hypercholesterolemia (FH)." | 7.71 | Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. ( Knuuti, J; Laakso, J; Laaksonen, R; Laine, H; Päivä, H; Raitakari, OT, 2002) |
| "The goal of this study was to examine the relationship between plasma asymmetric dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects with borderline hypertension (BHT) and familial hypercholesterolemia (FH)." | 3.71 | Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. ( Knuuti, J; Laakso, J; Laaksonen, R; Laine, H; Päivä, H; Raitakari, OT, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sbrana, F | 2 |
| Pasanisi, EM | 2 |
| Dal Pino, B | 2 |
| Bigazzi, F | 2 |
| Sampietro, T | 2 |
| Petersen, C | 1 |
| Coceani, M | 1 |
| Ripoli, A | 1 |
| Pianelli, M | 1 |
| Luciani, R | 1 |
| Päivä, H | 1 |
| Laakso, J | 1 |
| Laine, H | 1 |
| Laaksonen, R | 1 |
| Knuuti, J | 2 |
| Raitakari, OT | 2 |
| Pitkänen, OP | 1 |
| Niinikoski, H | 1 |
| Nuutila, P | 1 |
| Iida, H | 1 |
| Voipio-Pulkki, LM | 1 |
| Härkönen, R | 1 |
| Wegelius, U | 1 |
| Rönnemaa, T | 1 |
| Viikari, J | 1 |
| Yokoyama, I | 2 |
| Murakami, T | 1 |
| Ohtake, T | 2 |
| Momomura, S | 2 |
| Nishikawa, J | 2 |
| Sasaki, Y | 2 |
| Omata, M | 2 |
6 other studies available for dipyridamole and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Diagnostic value of coronary flow reserve determined by echo dipyridamole stress in homozygous familial hypercholesterolemia.
Topics: Coronary Circulation; Dipyridamole; Echocardiography, Stress; Humans; Hyperlipoproteinemia Type II; | 2021 |
LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease.
Topics: Adult; Aged; Biomarkers; Blood Component Removal; Case-Control Studies; Chronic Disease; Dipyridamol | 2017 |
Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia.
Topics: Adult; Age Factors; Arginine; Biomarkers; Blood Flow Velocity; Case-Control Studies; Coronary Circul | 2002 |
Coronary flow reserve is impaired in young men with familial hypercholesterolemia.
Topics: Adult; Age Factors; Cholesterol; Cholesterol, LDL; Coronary Circulation; Coronary Disease; Dipyridam | 1996 |
Reduced coronary flow reserve in familial hypercholesterolemia.
Topics: Ammonia; Cholesterol; Coronary Artery Disease; Coronary Circulation; Dipyridamole; Female; Humans; H | 1996 |
Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis.
Topics: Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cineangiography; Coronary Angiograp | 1996 |